Spring Bank Pharmaceuticals Inc (SBPH) Holdings Boosted by Morse Asset Management Inc
Morse Asset Management Inc grew its holdings in Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) by 18.4% during the fourth quarter, HoldingsChannel reports. The firm owned 146,875 shares of the company’s stock after acquiring an additional 22,875 shares during the period. Morse Asset Management Inc’s holdings in Spring Bank Pharmaceuticals were worth $1,821,000 at the end of the most recent reporting period.
A number of other institutional investors have also bought and sold shares of SBPH. DAFNA Capital Management LLC acquired a new position in Spring Bank Pharmaceuticals in the second quarter worth $217,000. Vanguard Group Inc. acquired a new position in Spring Bank Pharmaceuticals in the second quarter worth $794,000. Sectoral Asset Management Inc acquired a new position in Spring Bank Pharmaceuticals in the second quarter worth $1,523,000. C WorldWide Group Holding A S boosted its stake in Spring Bank Pharmaceuticals by 342.6% in the third quarter. C WorldWide Group Holding A S now owns 111,200 shares of the company’s stock worth $1,873,000 after purchasing an additional 86,077 shares in the last quarter. Finally, Parsons Capital Management Inc. RI boosted its stake in Spring Bank Pharmaceuticals by 2.2% in the third quarter. Parsons Capital Management Inc. RI now owns 281,728 shares of the company’s stock worth $4,744,000 after purchasing an additional 6,000 shares in the last quarter. 29.70% of the stock is currently owned by institutional investors.
A number of research firms have commented on SBPH. Chardan Capital reissued a “buy” rating on shares of Spring Bank Pharmaceuticals in a research note on Monday, November 6th. ValuEngine lowered Spring Bank Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. B. Riley began coverage on Spring Bank Pharmaceuticals in a research note on Monday, November 6th. They issued a “buy” rating and a $30.00 price objective on the stock. Finally, Cantor Fitzgerald set a $29.00 price objective on Spring Bank Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, November 16th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. Spring Bank Pharmaceuticals has an average rating of “Buy” and a consensus target price of $27.25.
Spring Bank Pharmaceuticals (NASDAQ:SBPH) last released its earnings results on Tuesday, October 31st. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.07. sell-side analysts expect that Spring Bank Pharmaceuticals Inc will post -2.94 EPS for the current fiscal year.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.
Want to see what other hedge funds are holding SBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH).
Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.